Clarivate and KYBORA Partner to Help Biopharma Companies Execute Strategic Transaction Outcomes
This collaboration combines the scientific and commercial expertise of Clarivate’s Life Sciences & Healthcare Consulting practice with KYBORA’s global transaction execution capabilities to accelerate life sciences transactions
London, U.K., August 13, 2026 — Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a partnership with KYBORA, a global investment bank focused on supporting biopharma leaders to close the right strategic transactions. Together, the companies will provide integrated, end-to-end transaction advisory services designed to help life sciences companies maximize the value of their innovations and navigate complex strategic transactions with greater confidence.
Dr. Srikanth Rajagopal, Vice President, Commercial Consulting, Life Sciences & Healthcare, Clarivate, said: “Biopharma companies are under increasing pressure to translate scientific innovation into clear, investable opportunities in a highly competitive and resource-constrained environment. This partnership strengthens our ability to connect scientific, clinical and commercial insight so clients can better understand asset value, shape stronger investment narratives and make more informed strategic decisions.”
Alan Vanderborght, CEO & Founder, KYBORA, said: “Successful transactions depend on more than strong assets. They require alignment between data, positioning, and investor priorities from the outset. By combining our global network of decision-makers and transaction execution expertise with Clarivate’s deep life sciences intelligence, we are helping biopharma leaders engage the right partners earlier, sharpen deal positioning, and close the right transactions. with high quality and high pace of execution.”
As biopharma companies face increasing pressure to secure capital, differentiate assets and accelerate growth, demand is rising for integrated scientific, commercial and transaction expertise. The partnership combines Clarivate’s trusted life sciences data, proprietary content and the scientific, clinical, commercial and strategic expertise of its Life Sciences & Healthcare Consulting practice with KYBORA’s biopharma operational expertise, investment banking experience and transaction capabilities across mergers and acquisitions, licensing and capital raising.
Together, the companies help clients evaluate opportunities, define asset value, strengthen investment narratives, and execute strategic transactions with greater confidence by combining trusted life sciences intelligence with deep transaction expertise. Backed by a global network of trusted relationships, KYBORA has completed nearly 100 biopharma M&A, licensing and fundraising transactions worldwide. With teams serving clients across North America, Europe, Latin America, and Asia Pacific, Clarivate and KYBORA provide access to key biopharma markets and investor communities worldwide, extending their reach to better support clients throughout the deal lifecycle.
Learn how Clarivate and KYBORA help biopharma companies maximize asset value and execute strategic transactions with confidence, here.
About KYBORA
KYBORA is a global investment bank whose mission is to guide transformative biopharma companies to enduring success globally. We work with biopharma leaders who use strategic transactions to create long -term value for their companies, their shareholders, and the patients they serve. For more information, please visit Kybora.com
About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.
Media Contact
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare, Clarivate
